The timeframe for experiencing substantial results with semaglutide GLP-1 varies depending on individual factors, including your initial weight, dietary choices, exercise routine, and overall health status
Slowing digestion so I feel satisfied for longer
The convergence of negotiated government pricing, the BALANCE Model, generic liraglutide availability, oral GLP-1 formulations, and next-generation agents like CagriSema and retatrutide suggests that coverage will continue expanding but with stronger cost management tools
UK prescribing should follow SmPC and NICE guidance
Overall, CT-388 has yielded promising results in terms of safety, tolerability, and efficacy for the treatment of obesity, with data supporting further clinical development and exploration at higher doses